AU2003258452A1 - Rna interference based methods and compositions for inhibiting hbv gene expression - Google Patents

Rna interference based methods and compositions for inhibiting hbv gene expression

Info

Publication number
AU2003258452A1
AU2003258452A1 AU2003258452A AU2003258452A AU2003258452A1 AU 2003258452 A1 AU2003258452 A1 AU 2003258452A1 AU 2003258452 A AU2003258452 A AU 2003258452A AU 2003258452 A AU2003258452 A AU 2003258452A AU 2003258452 A1 AU2003258452 A1 AU 2003258452A1
Authority
AU
Australia
Prior art keywords
compositions
gene expression
rna interference
based methods
interference based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003258452A
Other versions
AU2003258452A8 (en
Inventor
Jing Cheng
Yong Guo
Duanqing Pei
Fangxun Wang
Hongying Yin
Xin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
CapitalBio Corp
Original Assignee
Capital Biochip Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Biochip Corp filed Critical Capital Biochip Corp
Publication of AU2003258452A8 publication Critical patent/AU2003258452A8/en
Publication of AU2003258452A1 publication Critical patent/AU2003258452A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
AU2003258452A 2003-03-05 2003-08-25 Rna interference based methods and compositions for inhibiting hbv gene expression Abandoned AU2003258452A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN03119222.X 2003-03-05
CNB03119222XA CN1257284C (en) 2003-03-05 2003-03-05 Method of blocking expression of hepatitis B virus
PCT/CN2003/000718 WO2004078181A1 (en) 2003-03-05 2003-08-25 Rna interference based methods and compositions for inhibiting hbv gene expression

Publications (2)

Publication Number Publication Date
AU2003258452A8 AU2003258452A8 (en) 2004-09-28
AU2003258452A1 true AU2003258452A1 (en) 2004-09-28

Family

ID=32932360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003258452A Abandoned AU2003258452A1 (en) 2003-03-05 2003-08-25 Rna interference based methods and compositions for inhibiting hbv gene expression

Country Status (4)

Country Link
KR (1) KR20060029597A (en)
CN (1) CN1257284C (en)
AU (1) AU2003258452A1 (en)
WO (1) WO2004078181A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2005014806A2 (en) 2003-06-12 2005-02-17 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
EP1789447B1 (en) 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
CN1312283C (en) * 2004-12-07 2007-04-25 浙江大学 Smal linterference ribonucleic acid sequence of hepatitis B virus gene and preparing method
ATE507293T1 (en) * 2004-12-22 2011-05-15 Alnylam Pharmaceuticals Inc CONSERVED HBV AND HCV SEQUENCES SUITABLE FOR GENE SILENCING
WO2006096018A1 (en) * 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
CN100420749C (en) * 2006-02-10 2008-09-24 南京吉脉生物技术有限公司 Application of ShRNA pointed at HBV gene in inhibiting hepatitis B virus duplication
GB2439543A (en) * 2006-06-27 2008-01-02 Viruvation B V Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences
WO2010012244A1 (en) * 2008-08-01 2010-02-04 苏州瑞博生物技术有限公司 Small rna interference target site sequences of hepatitis b virus and small interference rnas and the compositions and uses thereof
US8598334B2 (en) * 2009-10-16 2013-12-03 Glaxo Group Limited HBV antisense inhibitors
WO2012045894A1 (en) * 2010-10-05 2012-04-12 Proyecto De Biomedicina Cima, S.L. Compounds and compositions for the treatment of illnesses caused by the hepatitis b virus
CN101979556B (en) * 2010-10-28 2015-01-21 百奥迈科生物技术有限公司 Small interfering ribose nucleic acid (siRNA) targeting molecule and application thereof
CN101979553B (en) * 2010-10-28 2015-07-01 百奥迈科生物技术有限公司 siRNA molecule for interfering HBV gene and antiviral application thereof
CN101979554B (en) * 2010-10-28 2015-08-26 百奥迈科生物技术有限公司 A kind of siRNA molecule and application thereof disturbing HBV gene
CN102021170B (en) * 2010-10-28 2015-07-01 百奥迈科生物技术有限公司 Small interfering ribonucleic acid (siRNA) molecule of interfering hepatitis B virus gene and application thereof
CN101979558B (en) * 2010-10-28 2015-09-02 百奥迈科生物技术有限公司 A kind of siRNA molecule of target hepatitis B virogene and application thereof
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
EP2699583A4 (en) 2011-04-21 2015-04-15 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
EP2966170A1 (en) * 2014-07-10 2016-01-13 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - HBV inactivation
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20180038465A (en) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 RNAi therapy for hepatitis B virus infection
ES2929928T3 (en) 2015-11-09 2022-12-05 Purotech Bio Inc Compounds for use in the treatment of conditions related to HBV and HCV
RU2021113126A (en) 2016-05-05 2021-08-20 Бенитек Байофарма Лимитед DRUGS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND THEIR APPLICATION
KR101879329B1 (en) 2016-06-13 2018-07-17 충북대학교 산학협력단 RNA-seq expression data simulation method for differential gene expression analysis, and recording medium thereof
JOP20170161A1 (en) * 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc RNAi Agents for Hepatitis B Virus Infection
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
RS64001B1 (en) 2017-10-20 2023-03-31 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
WO2019105419A1 (en) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Nucleic acid, composition and conjugate containing same, preparation method, and use
WO2019105435A1 (en) * 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
AU2018374219C1 (en) 2017-12-01 2023-05-11 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
SG11202100715WA (en) 2018-08-13 2021-02-25 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2020038377A1 (en) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. Sirna conjugate, preparation method therefor and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554376A4 (en) * 1990-10-22 1994-08-24 Fox Chase Cancer Center Dna construct for providing rna therapy
CN1215058A (en) * 1997-10-21 1999-04-28 中国科学院上海生物化学研究所 Novel trichain formed eliyonucleotide structure and application to anti-virus of hepatitis B
WO2002083908A1 (en) * 2001-03-30 2002-10-24 Fundacion Para La Investigacion Medica Aplicada Method for reversible inhibition of gene expression by modified ribonucleoproteins

Also Published As

Publication number Publication date
WO2004078181A1 (en) 2004-09-16
KR20060029597A (en) 2006-04-06
AU2003258452A8 (en) 2004-09-28
CN1257284C (en) 2006-05-24
CN1526818A (en) 2004-09-08

Similar Documents

Publication Publication Date Title
AU2003258452A1 (en) Rna interference based methods and compositions for inhibiting hbv gene expression
AU2003261449A1 (en) Compositions for rna interference and methods of use thereof
AU2003257013A1 (en) Methods and compositions for amplification of dna
AU2003279010A1 (en) Compositions and methods for delivery of short interfering rna and short hairpin rna
EP1742958A4 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP1546397A4 (en) Cell-based rna interference and related methods and compositions
AU2003297474A1 (en) Methods of inhibiting gene expression by rna interference
AU2003290710A1 (en) Muc1 interference rna compositions and methods derived therefrom
AU2003295539A1 (en) Allele-targeted rna interference
AU2003256249A1 (en) Compositions and methods for suppressing eukaryotic gene expression
GB2442373B (en) Sequence -specific inhibition of small rna function
IL237721B (en) Nucleic acid-lipid particles comprising interfering rna, compositions comprising same and uses thereof
AU2003290598A1 (en) Modified oligonucleotides for use in rna interference
EP1942948A4 (en) Compositions and methods for inhibiting expression of nav1.8 gene
AU2003248862A1 (en) Compositions and fabrication methods for hardmetals
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2003239129A1 (en) Methods and compositions for dna manipulation
AU2003270310A1 (en) Compositions and methods for synthesizing nucleic acids
EP1590002A4 (en) Small interference rna gene therapy
AU2003287254A1 (en) Inhibition of gene expression using rna interfering agents
GB0608813D0 (en) Improved methods and compositions for RNA interference
AU2003222197A1 (en) Inhibition of rna function
AU2005270917A8 (en) Gastrin-specific interfering RNA
EP1652917A4 (en) Rna capable of inhibiting expression of klf5 gene
AU2001283226A1 (en) Methods and compositions for inhibiting rad51

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase